SCHEMBL3017259

SCHEMBL3017259

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)c(F)c4)cs3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.52
USP2 O75604 3/20 0.52
HSD17B10 Q99714 2/20 0.52
RECQL P46063 1/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 9/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 8/20 0.46
LMNA P02545 7/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM1A O60341 1/20 0.45
AR P10275 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 3/20 0.42
HTT P42858 2/20 0.42
TSHR P16473 1/20 0.42
GAA P10253 1/20 0.42
MMP1 P03956 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008539 0.93 MAPT (0.52) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3012817 0.92 SMN1; SMN2 (0.54) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3008106 0.92 SMN1; SMN2 (0.54) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3008886 0.90 SMN1; SMN2 (0.49) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3012939 0.90 SMN1; SMN2 (0.57) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3011169 0.90 SMN1; SMN2 (0.49) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3021149 0.90 SMN1; SMN2 (0.51) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3008616 0.90 SMN1; SMN2 (0.44) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3016975 0.89 SMN1; SMN2 (0.54) MAPTUSP2HSD17B10RECQLSMN1; SMN2
SCHEMBL3019373 0.89 SMN1; SMN2 (0.50) MAPTUSP2HSD17B10RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.